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A series of acyl esters of 3,17-β-estradiol has been prepared by an enzymatic methodology. 
Eleven 17-monoacyl products (five novel compounds) were obtained in a highly regioselective 
way by acylation of 3,17-β-estradiol or by alcoholysis of the corresponding diacyl derivatives. 
The influence of various reaction parameters such as molar ratio, enzyme:substrate ratio and 
temperature was evaluated. Among the tested lipases, Candida rugosa lipase appeared to be the 
most appropriate in monoacylation and lipase from Candida antarctica in alcoholysis. The 
advantages presented by this methodology such as mild reaction conditions, economy and low 
environmental impact, make the biocatalysis a convenient way to prepare monoacyl derivatives 
of 3,17-β-estradiol containing the aromatic 3-hydroxyl group free. Some of these compounds are 
recongnized as useful products in the pharmaceutical industry. 
 






Human estrogens, such as 3,17-β-estradiol 1, are known to exert powerful antioxidant effects in 
lipid-aqueous systems in vitro.1-3 The antioxidant efficacy appears to depend on unsubstituted 
hydroxyl groups on the aromatic ring A of estrogen molecules,4-7 a structure similar to that seen 
in other natural antioxidants such as α-tocopherol 2 and several isoflavone phytoestrogens as 
well as flavones (Figure 1).8 
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The identification of estradiol esters formed by lecithin:cholesterol acyltransferase9 and the 
esterification site of estradiol at C-17 in the D ring,10 suggested that these derivatives might 
become structural components in lipoproteins. These lipoprotein-associated molecules would be 
active possibly interfering with the atherosclerotic process. 
Fatty acid esterification of steroid hormones is a metabolic transformation which prolongs 
and potentiates hormonal activity, although the esters are prohormones which require hydrolytic 
cleavage for their activation.11 In theory, estrogen fatty acid esters could constitute a hormonal 
reservoir mainly residing in fat tissue.12 One may speculate that specific esterases might become 
activated and liberate the estrogens at times when steroidogenic organs become quiescent or lose 
their function.11
Although there is mounting evidence supporting important functions for steroid esters, all the 
functions remained speculative and further studies are of particular interest. Then, fatty acid 
monesters of 3,17-β-estradiol in the position 17 of ring D could be useful to ascertain the 
possible utility of estrogens as protective against atherosclerosis and to provide standards for 
metabolic studies. 
The regioselective tranformation of polyfunctional compounds such as steroids, is a 
challenging problem in organic synthesis, especially in case of a structure sensitive to acid, base, 
oxidation, or reduction, which limits the choice of reagents needed to accomplish a particular 
transformation. In recent years, lipases have become attractive as biocatalysts for chemo-, regio- 
and stereoselective reactions under mild conditions.13,14 They can be used in a wide variety of 
organic solvents and do not require a coenzyme for activity.15,16
Specifically in the steroids field, enzyme catalysis can play an important role for the mild and 
selective interconversion of functional groups via regioselective transformations.17-21 Studies 
carried out in our laboratory on the esterification and transesterification of polyfunctionalyzed 
steroids, have shown that lipases can act on substituents either on A-ring or on the D-ring. 22,23 
Thus, in previous papers we observed that, in androstanes and pregnanes, Candida rugosa lipase 
showed a preference for C-3 hydroxyl or acyloxy groups, whereas Candida antarctica catalyzed 
the reactions in D-ring.24,25
Since 17-monoacyl esters of 3,17-β-estradiol are biologically active compounds used as 
"long acting" estrogens, a simple and selective procedure to obtain them is required. In 
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continuation of our work on enzymatic transformation of steroids, we report in the present paper 




Results and Discussion 
 
We have prepared, under mild reaction conditions monoacylated derivatives of 3,17-β-estradiol 
in a regioselective way and in high yields. The different compounds have been obtained through 
acylation of the substrate or alcoholysis of the oleyl derivative using lipases from several sources 
as catalysts. 
 
1. Enzymatic acylation 
The enzyme-catalyzed acylation let to obtain, in a regioselective way, monoacylated derivatives 













3a R1 = CH3(CH2)3CO- R2 = CH3CH2- 
3a R1 = CH3(CH2)3CO- R2 = H 
3b R1 = CH3(CH2)4CO- R2 = H 
3d R1 = CH3(CH2)8CO- R2 = H 
3d R1 = CH3(CH2)10CO- R2 = H 
3e R1 = CH3(CH2)12CO- R2 = H 
3f R1 = CH3(CH2)14CO- R2 = H 
3g R1 = CH3(CH2)16CO- R2 = H 
3h R1 = CH3(CH2)7CH=CH(CH2)7CO- cis R2 = H 
3i R1 = CH3(CH2)7CH=CH(CH2)7CO- trans R2 = H 
3j R1 = CH3(CH2)3(CH2CH=CH)2(CH2)7CO- cis, cis R2 = H 
3k R1 = CH3(CH2CH=CH)3(CH2)7CO- cis, cis, cis R2 = H 
 
Scheme 1 
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1.a. Enzyme screening and solvent effect 
Several commercial lipases in different solvents were evaluated in the acylation reaction of 1 
with oleic acid: Candida rugosa lipase (CRL), Candida antarctica lipase B (CAL B); Lipozyme 
from the fungus Rizomucor miehei (LIP), pancreatin, porcine pancreatic lipase (PPL) and lipase 
from Pseudomonas sp. (PS-C). The solvents selected were acetone, t-butanol, t-amyl alcohol, 
diisopropyl ether and toluene. Reactions were carried out at 33°C using an enzyme: substrate 
ratio of 5 and acylating agent: estradiol ratio of 2.5. TLC monitoring allowed the identification of 
the lipase able to promote the monoacylation of 1. 
In the absence of biocatalyst no product was obtained and, among the tested lipases, only 
CRL gave satisfactory results. GC/MS analysis of the CRL-catalyzed esterification in toluene 
showed that this lipase was completely regioselective obtaining exclusively the oleyl derivative 
in 17 position 3h in 62% yield, whereas in diisopropylether a mixture of 3h and isopropyl oleate 
was obtained. 
Working in the above mentioned reaction conditions, it is known that microbial lipases 
accept equatorial 3β-OH (PSL, CRL) or axial 3α-OH (CAL B) of ring A in the steroidal 
skeleton, but none of the lipases tested in this case was active in acylation of the aromatic 3-
hydroxyl group in estradiol in the presence of solvents. 
The application of lipases let to obtain 17-monooleyl 3h derivative with a high degree of 
selectivity, achieving a remarkable improve to the chemical approach. According to literature it 
is not possible to obtain exclusively the product 3h. The chemical acylation of 1 with oleyl 
chloride in pyridine at 0°C affords a mixture of products: a major product which is the 3,17 
diester and two minor products corresponding to the C-3 monoester and C-17 monoester, as well 
as free estradiol.26,27
Considering the results of enzymatic screening, we observed that CRL was the enzyme of 
choice for the synthesis of 3,17-β-estradiol-17-oleate 3h using toluene as solvent and was then 
selected for any further experiments. 
 
1.b. Effect of nature of the acyl donor 
Using CRL in toluene we investigated the influence of the acyl donor on the reaction yield. 
Estradiol esterification with oleic acid was compared to transesterification using ethyl oleate as 
acyl donor. We observed that esterification with oleic acid was much better with more than 75 % 
formation of 3h while the use of ethyl ester gave very poor yield not exceeding 39% after 96 h. 
Interestingly, the same results were also reported by us in enzymatic acylation of pyridoxine28 
and dehydroepiandrosterone23 and other authors in the preparation of cholesterol-29 and 
phytosterols oleate.,30 Therefore, in all further experiments with CRL, esterification processes 
were chosen using free fatty acids as acyl donors. 
 
1.c. Effect of acylating agent : substrate ratio 
The effect of the influence of acylating agent: substrate ratio on reaction yield was evaluated in 
the esterification of estradiol 1 with oleic acid in toluene using CRL. Reaction courses were 
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followed by GC at 24 and 72 h of reaction. As expected, it was observed that a molar excess of 
fatty acid was advantageous for the reaction (Table 1) with 2.5:1 oleic acid/ estradiol ratio giving 
the best results (78 % esterification degree after 72 h, entry 2). A higher excess of fatty acid did 
not improve yields in comparison with 2.5 ratio. 
 




24 h 72 h 
1 1:1 34.6 56.7 
2 2.5:1 65.7 78.3 
3 5:1 62.4 73.5 
4 10:1 44.4 70.2 
5 20:1 38.5 63.9 
a Determined by GC analysis. E/S: 5, temperature: 55°C. 
 
1.d. Effect of enzyme:substrate ratio 
The influence of the enzyme:substrate ratio was evaluated with a 2.5:1 estradiol/oleic acid ratio 
varying the amount of CAL. 3,17-β-Estradiol-17-oleate 3h formation was then monitored at 72h 




















Figure 2. Effect of enzyme:substrate ratio on the CRL-catalyzed synthesis of 3,17-β-estradiol-
17-oleate (3h). Acylating agent /S: 2.5, temperature: 55°C, time 72h. 
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1.e. Influence of temperature on 3,17-β-Estradiol-17-oleate formation 
Temperatures of 33°C and 55°C were considered in reactions where the previously studied 
parameters were fixed to their optimal values (CRL, toluene, E/S: 5 and oleic acid/estradiol: 2.5). 
The obtained results: 62 % at 33°C and 79% at 55°C, showed a difference in terms of yields for 
the catalyzed reaction at both temperatures. So we decided to perform the reaction at 55°C. 
 
1.f. Application of the enzymatic acylation to several acylating agents 
The results obtained by means of the CRL catalyzed procedure to the preparation of 17-
monoacyl fatty acid derivatives of 3,17-β-estradiol are shown in Table 2. Variable chain length 
saturated and unsaturated carboxylic acids from 5 to 18 carbon atoms gave the monoacyl 
derivative exclusively in position 17 in high yield. The results show that the ester formation was 
not influenced by chain length nor by the presence or stereochemistry of double bonds. 
 
Table 2. Lipase-catalyzed synthesis of 3,17-β-estradiol-17-esters from carboxylic acids (3) 
Entry Product Acylating agent Yield (%) 
1 3ª Valeric acid 67 
2 3b Caproic acid 66 
3 3c Capric acid 69 
4 3d Lauric acid 73 
5 3e Myristic acid 78 
6 3f Palmitic acid 70 
7 3g Estearic acid 71 
8 3h Oleic acid 76 
9 3i Elaidic acid 75 
10 3j Linoleic acid 72 
11 3k Linolenic acid 77 
a Isolated products. E/S: 5, Acylating/S: 2.5, temperature: 55°C, time 72h. 
2. Enzymatic alcoholysis 
 
Another approach to obtain 3,17-β-estradiol-17-oleate 3h could be an enzymatic alcoholysis 
on the dioleyl derivative of 3,17-β-estradiol 4 (Scheme 2). 
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R1 = CH3(CH2)7CH=CH(CH2)7CO- cis





First, we prepared 4, following the reported chemical procedure with oleoyl chloride in 
pyridine at 0°C.27 This procedure afforded a mixture of products: a major product which is the 
3,17 diester and two minor products corresponding to the C-3 monoester and C-17 monoester, as 
well as free estradiol. The dioleoyl derivative 4 was isolated and purified by column 
chromatography. When we tested the performance of lipases in the preparation of 4, we observed 
that working without solvent at 55°C, CRL afforded the 3,17-dioleate in high purity and yield 
(92%). 
So we scaled up this procedure and then carried out the enzymatic alcoholysis of 3,17-β-
estradiol-dioleate 4. The best enzyme in this case was CAL B. The alcoholysis reaction was 
conducted with several alcohols as nucleophiles and solvent, leading to similar results with all of 
them (Table 3). 
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Table 3. Lipase-catalyzed alcoholysis of 3,17-β-estradiol-dioleate (4) 




a Determined by GC analysis. E/S: 5, temperature: 55°C. 
 
Although this enzymatic approach involving two steps: preparation and alcoholysis of 
estradiol dioleate 4, gave the products in excellent yield, 92% and 91% isolated products 
respectively, for preparative purposes the acylation procedure to obtain the 17-monoacyl 





Following an enzymatic methodology a series of acyl esters of 3,17-β-estradiol has been 
prepared. The 17-monoacyl products were obtained in a high regioselective way by acylation of 
3,17-β-estradiol or by alcoholysis of the corresponding diacyl derivatives. Five (3b, 3c, 3d, 3e 
and 3i) from the eleven compounds prepared, have not been described before. The influence of 
various reaction parameters was evaluated to determine the reaction conditions. Among the 
tested lipases, lipase from Candida rugosa appeared to be the most appropriate in the acylation 
reaction CAL B in the alcoholysis. It was observed that in the acylation, the direct esterification 
with fatty acids gave better results than transesterification with their ethyl esters. The advantages 
presented by this methodology such as mild reaction conditions, economy and low 
environmental impact, make the biocatalysis a convenient way to prepare in a regioselective 
way, monoacyl derivatives of 3,17-β-estradiol containing the aromatic 3-OH free. Some of these 
compounds (3a and 3h) are recognized as useful products in pharmaceutical industry and belong 





General Procedures. All solvents and reagents were reagent grade and used without 
purification. Lipase from Candida rugosa (CRL) (905 U/mg solid), pancreatin and type II crude 
from porcine pancreas (PPL) (190 U/mg protein) were purchased from Sigma Chemical Co.; 
Candida antarctica lipase B (CAL B): Novozym 435 (7400 PLU/g) and Lipozyme RM 1M 
(LIP) (7800 U/g) were generous gifts of Novozymes Latinoamerica Ltda and Novozymes A/S; 
Pseudomonas lipase: Lipase PS Amano (PSL) (33,200 U/g) was purchased to Amano 
Pharmaceutical Co. All enzymes were used "straight from the bottle". 
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Enzymatic reactions were carried out on Innova 4000 digital incubator shaker, New 
Brunswick Scientific Co. at 33°C and 55°C and 200 rpm. Melting points were measured in a 
Fisher Johns apparatus and are uncorrected. Enzymatic reactions were followed by TLC on 
Merck Silica gel 60F-254 aluminium sheets (0.2 mm thickness). For column chromatography 
Merck Silica gel 60 (60-230 mesh) was used. GC analyses were performed on a Hewlett 
Packard-5890 gas chromatograph, using HP-17 column (10mx0.53mmx0.20µm). The following 
temperature program was employed 100°C (1 min)/5°C/min/280°C (5 min). FT-IR spectra were 
obtained on a Shimadzu FTIR-8300 spectrophotometer.1H-NMR and 13C-NMR spectra were 
recorded at 500 MHz using Bruker AM-500 spectrometer. Chemical shifts are reported in δ units 
relative to tetramethylsilane (TMS) set at 0 δ, using CDCl3 as solvent, coupling constants are 
given in Hz. EI-MS were obtained at 70eV using a TRIO-2 VG Masslab Shimadzu QP-5000 and 
a Finnigan TSQ70 instrument mass spectrometers. 
 
Enzymatic monoacylation 
(17β)-Estra-1,3,5(10)-triene-3,17-diol cis-9-octadecenoate (3h). To a solution of 1 (1 g, 3.7 
mmol) in toluene (300 ml), 2.6 g (9.25 mmol) of oleic acid and 5 g of CRL were added. The 
suspension was stirred (200 rpm) at 55º C and the progress of reaction was monitored by TLC 
(hexane/dichloromethane 1:3)) and GC. After the indicated time, the enzyme was filtered off, the 
solvent evaporated, and the crude residue purified by silica gel chromatography (hexane: 
dichloromethane 1:3): 1.50 g (76%) of 3h. m. p.: 38-41°C. IR νmáx (cm-1) 3467 (OH), 3010, 
2933, 2861 (CH), 1702 (C=O). 1H NMR δ 0.83 (s, 3H), 0.88 (t, J = 7.02 Hz, 3H), 1.57-1.23 (m, 
28H), 1.67-1.60 (m, 2H), 1.78-1.70 (m, 1H), 1.90-1.84 (m, 2H), 2.02 (dd J = 12.3 Hz, 6.5 Hz, 
4H), 2.29-2.15 (m, 3H), 2.32 (t, J = 7.7 Hz, 2H), 2.85-2.80 (m 2H), 4.70 (dd, J = 9.06 Hz, 7.95, 
1H), 5,35 (m, 2H), 6.57 (d, J = 2.74 Hz, 1H), 6.64 (dd, J = 8.44 Hz, 2.75 Hz, 1H), 7.14 (d, J = 
8.35 Hz, 1H) ppm.  13C NMR (CDCl3): 12.15, 14.2, 22.5, 23.3, 25.2, 25.4, 25.7, 26.2, 27.1, 27.4, 
27.6, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 31.9, 34.7, 36.7, 38.5, 43.2, 49.8, 82.5, 112 .7, 115.3, 
126.6, 127.4, 127.8, 128.3, 130.4, 131.7, 132.6, 138.2, 153.4, 174.1 ppm. EI-MS: m/z (relative 
intensity): 536 [M+] (17), 281(2), 255 (100), 159 (67), 133 (37), 95 (15), 69 (25), 55 (40), 41 
(18).27
(17β)-Estra-1,3,5(10)-triene-3,17-diol pentanoate (3a). As described for 3h, but using 
pentanoic acid (940 mg) as acylating agent: 877 mg (67 %), m.p.: 146-7 °C (lit. 148 °C)31; 
IR νmáx (cm-1) 3440 (OH), 3015, 2985, 2885 (CH), 1700 (C=O). 1H-NMR δ 0.83 (s, 3H), 0.93 
(t, J = 7.42 Hz, 3H) , 1.48-122 (m, 8H) ), 1.58-1.49 (m, 1H), 1.69-1.59 (m, 2H) , 1.79-1.66 (m, 
2H), 1.90-1.82 (m, 2H), 2.30-2.15 (m, 3H), 2.32 (t, J = 7.4 Hz, 2H), 2.81 (m, 2H), 4.70 (dd, J = 
7.8 Hz, 8.0 Hz, 1H), 6.57 (d, J = 2.7 Hz, 1H), 6.63 (dd, J = 8.2 Hz, 2.7 Hz, 1H), 7.14 (d, J = 8.2 
Hz, 1H) ppm . 13C-NMR δ 12.1, 13.7, 22.2, 23.2, 26.1, 27.2, 27.3, 27.6, 29.6, 34.4, 36.9, 38.6, 
42.9, 43.7, 49.7, 82.5, 112.7, 115.2, 126.5, 132.5, 138.1, 153.4, 174.1 ppm. EI/MS m/z (relative 
intensity): 356 M+ (100), 85 (63), 57 (81), 41 (42). 
(17β)-Estra-1,3,5(10)-triene-3,17-diol hexanoate (3b). As described for 3h, but using hexanoic 
acid (1,08 g) as acylating agent: : 898 mg ( 66 %), m.p.: 118-121°C; IR νmáx (cm-1) 3438 (OH), 
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3018, 2980, 2880 (CH), 1710 (C=O). 1H NMR (CDCl3) δ 0.83 (s, 3H), 0..81 (t, J = 7.03 Hz, 3H), 
1.40-1.25 (m, 9H) , 1.64-1.60 (m, 4H), 1.77-1.71 (m, 2H), 1.89-1.84 (m, 2H), 2.28-2.17 (m, 3H), 
2.31 (t, J = 7.85 Hz, 2H), 2.82 (m, 2H), 4.69 (dd, J = 7.85 Hz, 9.08 Hz, 1H), 6.56 (d, J = 2.69 Hz, 
1H), 6.62 (dd, J = 8.41 Hz, 2.80 Hz, 1H), 7.14 (d, J = 8.30 Hz, 1H) ppm. 13C NMR (CDCl3) δ 
(ppm) : 12.1, 13.9, 22.3, 23.3, 24.8, 26.2, 27.2, 27.6, 29.6, 31.3, 34.6, 36.9, 38.5, 42.9, 43.8, 49.8, 
82.5, 112.7, 115.2, 126.5, 132.5, 138.2, 153.4, 174.1 ppm. EI-MS m/z (relative intensity): 
370[M+] (100), 254 (13), 225 (14), 172 (22), 159 (28), 146 (26), 133 (22), 99(28), 71 (33) 55 
(20), 43(72). HR-MS: 370.5359 (C24H34O3+; calc. 370.5366). 
(17β)-Estra-1,3,5(10)-triene-3,17-diol decanoate (3c). As described for 3h, but using decanoic 
acid (1.6g) as acylating agent: : 1.08 g ( 69 %), m.p.: 94-99°C; IR νmáx (cm-1) 3450 (OH), 3009, 
2989, 2853 (CH), 1701 (C=O). 1H NMR δ 0.76 (s, 3H), 0.84 (t, J = 7.05 Hz, 3H), 1.44-1.18 (m, 
17H), 1.61-1.54 (m, 4H), 1.71-1.64 (m, 2H), 1.83-1.78 (m, 2H), 2.22-2.11 (m, 3H), 2.25 (t, J = 
7.65 Hz, 2H), 2.79-2.73 (m, 2H), 4.64 (dd, J = 7.89 Hz, 9.09 Hz, 1H), 6.50 (d, J = 2.66 Hz, 1H), 
6.56 (dd, J = 8.40 Hz, 2.83 Hz, 1H), 7.08 (d, J = 8.48 Hz, 1H) ppm. 13C NMR (CDCl3) δ: 12.1, 
14.1, 22.7, 23.3, 25.1, 26.2, 27.1, 27.6, 29.1, 29.3, 29.4, 29.6, 29.7, 31.8, 34.6, 36.9, 38.5, 42.9, 
43.8, 49.8, 82.4, 112.6, 115.2, 126.5, 132.6, 138.2, 153.3, 174.1 ppm. EI-MS m/z (relative 
intensity): 426 [M+] (100), 254 (20), 172 (28), 159 (44), 146 (31), 133 (39), 71 (26), 57 (48) 43 
(78). HR-MS: 426.6454 (C28H42O3+; calc. 426.6450). 
(17β)-Estra-1,3,5(10)-triene-3,17-diol dodecanoate (3d). As described for 3h, but using 
dodecanoic acid (1.85 g) as acylating agent: :  1.22 g ( 73 %), m.p.: 70-71°C; IR νmáx (cm-1) 3460 
(OH), 3009, 2989, 2853 (CH), 1701 (C=O). 1H-NMR δ 0.83 (s, 3H), 0.88 (t, J = 7.45 Hz, 3H) , 
1.48-1.06 (m, 20H) ), 1.58-1.49 (m, 1H), 1.66-1.59 (m, 4H), 1.78-1.69 (m, 2H), 1.90-1.82 (m, 
2H), 2.20-2.14 (m, 3H), 2.32 (t, J = 7.7 Hz, 2H) , 2.82 (m, 2H), 4.70 (dd, J = 7.8 Hz, 8.0 Hz, 
1H), 6.55 (d, J = 2.8 Hz, 1H), 6.63 (dd, J = 8.5 Hz, 2.8, 1H), 7.14 (d, J = 8.2 Hz, 1H) ppm. 13C-
NMR δ 12.1, 14.1, 22.7, 23.2, 25.1 26.2, 27.1, 27.6, 29.1, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7,31.9, 
34.6, 36.9, 38.5, 42.9, 43.8, 49.8, 82.5, 112.7, 115.2, 126.5, 132.5, 138.1, 153.8, 174.2 ppm. 
EI/MS m/z (relative intensity): 454 [M+] (100), 255 (15), 159 (31), 57 (37), 43 (56). HR-MS: 
454.6995 (C30H46O3+; calc. 454.6992). 
(17β)-Estra-1,3,5(10)-triene-3,17-diol tetradecanoate (3e). As described for 3h, but using 
tetradecanoic acid (2.1 g) as acylating agent: :  1.38 g ( 78 %), m.p.: 68-72°C; IR νmáx (cm-1) 
3431 (OH), 3011, 2989, 2863 (CH), 1706 (C=O). 1H NMR δ 0.79 (s, 3H), 0.87 (t, J = 7.39 Hz, 
3H), 1.35-1.07 (m, 24H ), 1.61-1.47 (m, 1H), 1.65-1.57 (m, 4H), 1.74-1.67 (m, 2H), 1.89-1.79 
(m, 2H), 2.17-2.15 (m, 3H), 2.23 (t, J = 7.65 Hz, 2H), 2.87 (m, 2H), 4.78 (dd, J = 7.72 Hz, 8.10 
Hz, 1H), 6.55 (d, J = 2.72 Hz, 1H), 6.63 (dd, J = 8.48 Hz, 2.71, 1H), 7.14 (d, J = 8.19 Hz, 1H) 
ppm. 13C NMR δ 12.1, 14.1, 22.7, 23.3, 24.8, 26.2, 27.1, 27.6, 29.1, 29.2, 29.4, 29.5, 29.6, 29.7, 
29.7, 31.3, 34.6, 36.9, 38.5, 42.9, 43.8, 49.8, 82.5, 112.7, 115.2, 126.5, 132.5, 138.2, 153.4, 174.1 
ppm. EI-MS m/z (relative intensity): 482 [M+] (52), 255 (13), 172 (14), 159 (38), 146 (24), 133 
(23) ,71 (16), 43 (100). HR-MS: 482.7529 (C32H50O3+; calc. 482.7532). 
(17β)-Estra-1,3,5(10)-triene-3,17-diol hexadecanoate (3f). As described for 3h, but using 
hexadecanoic acid (2.4 g) as acylating agent: : 1.31 g ( 70 %), m.p.: 71-73°C. IR νmáx (cm-1) 3423 
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(OH), 3015, 2990, 2871 (CH), 1701 (C=O). 1H NMR δ 0.82 (s, 3H), 0.88 (t, J = 6.94 Hz, 3H) , 
1.55-1.22 (m, 3H), 1.65-1.22 (m, 4H), 1.78-1.70 (m, 1H), 1.90-1.84 (m, 2H), 2.26-2.15 (m, 3H), 
2.31 (t, J = 7.83 Hz, 3H), 2.85-2.80 (m, 1H), 4.69 (dd, J = 7.93 Hz, 9.10 Hz, 1H), 6.56 (d, J = 
2.67 Hz, 1H), 6.62 (dd, J = 8.42 Hz, 2.77 Hz, 1H), 7.14 (d, J = 8.32 Hz, 1H) ppm. 13C NMR δ 
12.1, 14.2, 23.3, 25.2, 26.2, 27.2, 27.6, 29.2, 29.3, 29.4, 29.5, 29.6, 29.6, 29.7, 29.7, 31.9, 34.7, 
36.9, 38.6, 43.0, 43.8, 49.8, 82.5, 112.7, 115.3, 126.6, 132.6, 138.2, 153.4, 174.1 ppm. EI-MS 
m/z (relative intensity): 510 [M+] (50), 255 (13), 172 (14), 159 (34), 146 (21), 133 (28) ,71 (16), 
43 (100).27
(17β)-Estra-1,3,5(10)-triene-3,17-diol octadecanoate (3g). As described for 3h, but using 
octadecanoic acid (2.63 g) as acylating agent: : 1.40 mg (71 %), m.p.: 65-67°C. IR νmáx 3439 
(OH), 3011, 2983, 2851 (CH), 1708 (C=O). 1H-NMR δ 0.83 (s, 3H), 0.88 (t, J = 7.0 Hz, 3H) , 
1.48-1.20 (m, 32H) ), 1.65-1.49 (m, 5H), 1.77-1.70 (m, 2H), 1.90-1.81 (m, 2H), 2.28-2.16 (m, 
3H), 2.31 (t, J = 7.1 Hz, 2H), 2.82 (m, 2H), 4.70 (dd, J = 7.6 Hz, 7.9 Hz, 1H), 6.55 (d, J = 2.9 
Hz, 1H), 6.63 (dd, J = 8.3 Hz, 2.9 Hz, 1H), 7.14 (d, J = 8.3 Hz, 1H) ppm. 13C-NMR δ 12.1, 14.2, 
22.7, 23.2, 25.2 26.3, 27.2, 27.6, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 29.8, 32.0, 34.7, 37.0, 38.6, 
43.0, 43.8, 49.8, 82.5, 112.7, 115.3, 126.6, 132.6, 138.2, 153.4, 174.1 ppm. EI/MS m/z (relative 
intensity): 538 [ M+] (100), 255 (35), 159 (60), 57 (53), 43 (78). 27
(17β)-Estra-1,3,5(10)-triene-3,17-diol trans-9-octadecenoate (3i). As described for 3h, but 
using trans-9-ocatadecenoic acid (2.6 g) as acylating agent: :  1.48 g ( 75 %), m.p.: 60-64°C; IR 
νmáx (cm-1) 3429 (OH), 3000, 2983, 2850 (CH), 1710 (C=O). 1H NMR δ 0.82 (s, 3H), 0.87 (t, J = 
6.95, 3H), 1.56-1.23 (m, 28H), 1.65-1.61 (m, 2H), 1.78-1.69 (m, 1H), 1.90-1.83 (m, 2H), 2.01 
(dd J = 12.3, 6.5 4H), 2.30-2.16 (m, 3H), 2.31 (t, J = 7.60 Hz, 2H), 2.85-2.80 (m 2H), 4.70 (dd, J 
= 9.06 Hz, 7.81 Hz, 1H), 5,35 (m, 2H), 6.57 (d, J = 2.74 Hz, 1H), 6.65 (dd, J = 8.37 Hz, 2.79 Hz, 
1H), 7.14 (d, J = 8.37 Hz, 1H) ppm. 13C NMR (CDCl3): 12.1, 14.2, 22.7, 23.3, 25.1, 25.5, 25.6, 
26.3, 27.2, 27.3, 27.6, 29.1, 29.2, 29.4, 29.6, 29.7, 29.7, 31.9, 33.8, 36.9, 38.6, 43.8, 49.8, 82.5, 
112.8, 115.3, 126.6, 127.2, 127.6, 128.3, 130.3, 131.0 131.9, 138.2, 153.4, 174.1 ppm. EI-MS 
m/z (relative intensity): 536 [M+] (20), 255 (100), 159 (74), 133 (37), 95 (13), 69 (21), 55 (43), 
41 (29). HR-MS: 536.8450 (C36H56O3+; calc. 536.8459). 
(17β)-Estra-1,3,5(10)-triene-3,17-diol cis,cis-9,12-octadecadienoate (3j). As described for 3h, 
but using cis,cis-9,12-octadecadienoic acid (2.6 g) as acylating agent: 1.41 g ( 72%). m.p.: 35-
37°C. IR νmáx (cm-1) 3414 (OH), 3005, 2981,2849 (CH), 1703 (C=O). 1H-NMR δ 0.83 (s, 3H), 
0.88 (t, J = 7.0 Hz, 3H) , 1.48-1.18 (m, 13H)), 1.57-1.39(m, 3H),1.67-1.58 (m, 5H), 1.78-1.69 
(m, 2H), 1.90-1.82 (m, 2H), 2.11-1.92(m,4H,) 2.28-2.12 (m, 3H), 2.31 (t, J = 7.2 Hz, 2H), 2.1 
(m, 4H), 4.70 (dd, J = 7.9 Hz, 7.9 Hz, 1H), 5.43-5.27 (m,4H), 6.55 (d, J = 2.5 Hz, 1H), 6.63 (dd, 
J = 8.3 Hz, 2.5 Hz, 1H), 7.14 (d, J = 8.3 Hz, 1H) ppm. 13C-NMR δ 12.1, 14.2, 22.7, 23.3, 25.1, 
25.5, 25.6, 26.3, 27.2, 27.3, 27.6, 29.1, 29.2, 29.4, 29.6, 29.7, 29.8, 31.9, 34.6, 36.9, 38.6, 43.8, 
49.8, 82.5, 112.8, 115.3, 126.6, 127.2, 127.6, 128.3, 130.3, 132.0 132.5, 138.2, 153.4, 174.1 
ppm. EI/MS m/z (relative intensity): 532 [M+] (100), 255 (35), 133 (29), 55 (48), 41 (67). 27
3,17-β-Estradiol-17-cis,cis,cis-9,12,15-octadecatrienoate (3k). As described for 3h, but using 
cis,cis,cis-9,12,15-octadecatrienoic acid (2.6 g) as acylating agent: 1.51 g (77 %). Oil. IR νmáx 
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(cm-1) 3433 (OH), 3010, 2980,2846 (CH), 1705 (C=O).1H-NMR δ 0.83 (s, 3H), 0.88 (t, J = 7.0 
Hz, 3H), 1.48-1.18 (m, 11H)), 1.57-1.39(m, 3H),1.67-1.58 (m, 5H), 1.78-1.69 (m, 2H), 1.90-1.82 
(m, 2H), 2.11-1.92(m,4H,) 2.28-2.12 (m, 3H), 2.31 (t, J = 7.2 Hz, 2H) , 2.1 (m, 4H), 4.70 (dd, J 
= 7.9 Hz, 7.9 Hz, 1H), 5.43-5.27 (m,6H), 6.55 (d, J = 2.5 Hz, 1H), 6.63 (dd, J = 8.3 Hz, 2.5 Hz, 
1H), 7.14 (d, J = 8.3 Hz, 1H) ppm. 13C-NMR δ 12.1, 14.2, 22.7, 23.3, 25.1, 25.5, 25.6, 26.3, 
27.2, 27.3, 27.6, 29.1, 29.2, 29.4, 29.6, 29.7, 29.8, 31.9, 34.6, 36.9, 38.6, 43.8, 49.8, 82.5, 112.8, 
115.3, 126.6, 127.2, 127.6, 128.3, 130.3, 132.0 132.5, 138.2, 153.4, 174.1 ppm. EI/MS m/z 




It was prepared as described in reference 27 with 10 g of 3,17-β-estradiol. The dioleate 4 was 
isolated from the mixture of products by column chromatography (hexane/dichloromethane 1:3). 
Yield: 6.8 g (57%). Oil. IR νmáx (cm-1) 3007, 2990, 2835 (CH), 1735, 1702 (C=O). 1H-NMR 0.83 
(s, 3H), 0.88 (t, J = 6.9 Hz, 6H) , 1.58-1.20 (m, 44H)), 1.67-1.60 (m, 6H), 1.78-1.70 (m, 2H), 
1.90-1.82 (m, 2H), 2.11-1.95(m, 8H,) 2.28-2.20 (m, 3H), 2.31 (t, J = 7.0 Hz, 4H) , 2.89-2.83 (m, 
2H). 4.70 (dd, J = 7.9 Hz, 7.9 Hz, 1H), 5.39-5.30 (m, 4H), 6.78 (d, J = 2.5 Hz, 1H), 6.82 (dd, J = 
8.5 Hz, 2.5 Hz, 1H), 7.27 (d, J = 8.5 Hz, 1H) ppm.13C-NMR δ 12.1, 14.1, 21.1, 22.7, 23.2, 25.0, 
25.1, 26.1, 27.0, 27.1, 27.2, 27.6, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 29.8, 31.9, 34.4, 
34.6, 36.9, 38.2, 43.0, 44.0, 49.8, 82.5, 118.6, 121.4, 126.3, 129.6, 129.7, 129.9, 130.0, 137.7, 
138.1, 148.5, 172.5, 173.9 ppm. EI/MS m/z (relative intensity): 535 (25), 279 (15), 133 (29), 55 
(100), 41 (43). 
 
Enzymatic synthesis 
To a solution of 1 (1 g, 3.7 mmol), 9.8 g (34.5 mmol) of oleic acid and 5 g of CRL were added. 
The suspension was stirred (200 rpm) at 55º C and the progress of reaction was monitored by 
TLC (hexane/dichloromethane 1:3) and GC. After 72 h, 100 ml of dichloromethane were added 
and the enzyme was filtered off. The solvent was evaporated, and the crude residue was purified 
by silica gel chromatography (hexane/dichloromethane 1:3): 2.7 g (92%) of 4. Spectroscopic 
data were in accordance with 4 obtained by chemical synthesis. 
 
Enzymatic alcoholysis of 3,17-β-estradiol-cis-9-dioctadecenoate (4) 
To a solution of 4 (500 mg (0.62 mmol)) in 10 ml of alcohol, 2.5 g of CAL B were added. The 
suspension was shaken (200 rpm) at 55°C and the progress of reaction was monitored by GC. 
After 72 h, the enzyme was filtered off, the solvent evaporated, and the crude residue was 
purified by silica gel chromatography (hexane:dichloromethane 1:3): 316 mg (95%) of 3h 
Spectroscopic data were in accordance with 3h obtained by enzymatic acylation of 1. 
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